| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,287,264 | 3 | 100 |
| Holzer Phil M | SVP and Controller | 0 | $0 | 1 | $33,750 | $-33,750 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | 0 | $0 | 1 | $403,498 | $-403,498 |
| Elkins David V | EVP, Chief Financial Officer | 0 | $0 | 1 | $1.85M | $-1.85M |
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke …
Over the last 12 months, insiders at Bristol-Myers Squibb Company have bought $0 and sold $2.29M worth of Bristol-Myers Squibb Company stock.
On average, over the past 5 years, insiders at Bristol-Myers Squibb Company have bought $592,680 and sold $17.38M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,250 shares for transaction amount of $202,215 was made by Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) on 2025‑04‑25.
| 2026-09-09 | Sale | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | 6,249 0.0003% | $64.57 | $403,498 | -4.44% | |
| 2026-08-25 | Sale | Holzer Phil M | SVP and Controller | 500 <0.0001% | $67.50 | $33,750 | -8.13% | |
| 2026-04-01 | Sale | Elkins David V | EVP, Chief Financial Officer | 30,000 0.0015% | $61.67 | $1.85M | -1.79% | |
| 2025-09-02 | Sale | Elkins David V | EVP, Chief Financial Officer | 56,000 0.0027% | $47.33 | $2.65M | +23.42% | |
| 2025-08-02 | Sale | Short Bartie Wendy | EVP, Corporate Affairs | 378 <0.0001% | $44.23 | $16,719 | +3.66% | |
| 2025-05-09 | Sale | Hickey Benjamin | President, RayzeBio Org. | 97.39 <0.0001% | $38.01 | $3,702 | +5.65% | |
| 2025-04-25 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 4,250 0.0002% | $47.58 | $202,215 | +2.02% | ||
| 2025-02-20 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $55.05 | $110,096 | -11.77% | ||
| 2025-02-14 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1,823.49 <0.0001% | $54.84 | $100,000 | -8.68% | ||
| 2024-11-04 | Sale | Holzer Phil M | SVP and Controller | 700 <0.0001% | $55.62 | $38,931 | -9.46% | |
| 2024-11-01 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1,830 <0.0001% | $54.67 | $100,055 | -7.37% | ||
| 2023-12-05 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $49.78 | $99,560 | +1.37% | ||
| 2023-11-28 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 3,071 0.0002% | $48.86 | $150,049 | +3.87% | ||
| 2023-11-20 | Samuels Theodore R. II | director | 8,500 0.0004% | $49.81 | $423,385 | +3.54% | ||
| 2023-08-24 | Sale | Powell Ann | EVP, Chief Human Resources | 17,986 0.0009% | $61.25 | $1.1M | -16.48% | |
| 2023-08-03 | Sale | Plenge Robert M | EVP, Chief Research Officer | 732 <0.0001% | $61.14 | $44,754 | -16.04% | |
| 2023-05-03 | Sale | VESSEY RUPERT | EVP & President, Research | 50,385 0.0024% | $67.06 | $3.38M | -17.49% | |
| 2023-02-06 | Sale | Caforio Giovanni | Board Chair and CEO | 240,000 0.0115% | $74.65 | $17.92M | -15.58% | |
| 2023-02-06 | Sale | Powell Ann | EVP, Chief Human Resources | 11,183 0.0005% | $74.69 | $835,258 | -15.58% | |
| 2022-11-09 | Sale | Powell Ann | EVP, Chief Human Resources | 16,250 0.0008% | $80.45 | $1.31M | -15.72% |
| CELGENE CORP /DE/ | 10 percent owner | 7008510 0.3429% | $432.5M | 1 | 1 | +6.26% |
| SIGAL ELLIOT | EVP, CSO & President R&D | 148221 0.0073% | $9.15M | 1 | 10 | +21.49% |
| CORNELIUS JAMES M | director | 119464 0.0058% | $7.37M | 2 | 116 | +5.49% |
| BOERNER CHRISTOPHER S. | Chief Executive Officer | 104626 0.0051% | $6.46M | 3 | 1 | <0.0001% |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 83513 0.0041% | $5.15M | 3 | 0 | <0.0001% |
| Samuels Theodore R. II | director | 35500 0.0017% | $2.19M | 5 | 0 | +7.17% |
| Huet Jean-Marc | EVP & CFO | 25000 0.0012% | $1.54M | 1 | 0 | +21.49% |
| Paliwal Dinesh C | director | 22109 0.0011% | $1.36M | 2 | 0 | +7.66% |
| BERTOLINI ROBERT J | director | 11397 0.0006% | $703,308.87 | 1 | 0 | +34.5% |
| BONNEY MICHAEL W | director | 7189 0.0004% | $443,633.19 | 1 | 0 | +5.26% |
| GROBSTEIN MICHAEL | director | 3383 0.0002% | $208,764.93 | 2 | 1 | +5.48% |
$1,927,310,793 | 31 | 28.02% | $1,325.87B | |
$364,368,632 | 29 | 9.65% | $36.8B | |
$6,224,380 | 25 | 3.58% | $640.75B | |
Bristol-Myers Squibb Company (BMY) | $23,541,811 | 22 | 6.43% | $126.14B |
$28,542,809 | 19 | 26.39% | $505.4B |
| Increased Positions | 1,250 | +49.19% | 139M | +8.62% |
| Decreased Positions | 1,136 | -44.71% | 108M | -6.7% |
| New Positions | 353 | New | 28M | New |
| Sold Out Positions | 154 | Sold Out | 9M | Sold Out |
| Total Postitions | 2,655 | +4.49% | 2B | +1.92% |
| Vanguard Group Inc | $10.48M | 9.63% | 195.98M | +1M | +0.54% | 2025-09-30 |
| Blackrock, Inc. | $9.38M | 8.62% | 175.52M | +3M | +1.91% | 2025-09-30 |
| State Street Corp | $5.16M | 4.74% | 96.6M | +2M | +1.96% | 2025-09-30 |
| Jpmorgan Chase & Co | $4.61M | 4.23% | 86.18M | -18M | -17.1% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $3.9M | 3.59% | 73.04M | +2M | +3.16% | 2025-09-30 |
| Geode Capital Management, Llc | $2.49M | 2.29% | 46.55M | +377,610 | +0.82% | 2025-09-30 |
| Norges Bank | $1.79M | 1.65% | 33.57M | -2M | -4.55% | 2025-06-30 |
| Ameriprise Financial Inc | $1.74M | 1.6% | 32.47M | -105,784 | -0.33% | 2025-09-30 |
| Capital International Investors | $1.73M | 1.59% | 32.39M | -34M | -51.05% | 2025-09-30 |
| Morgan Stanley | $1.49M | 1.37% | 27.87M | +1M | +3.95% | 2025-09-30 |